View Older Stories View More Recent Stories
-
Bristol-Myers Squibb Prices $1.5 Billion of Senior Notes
-
Tepper's Appaloosa Enters American Airlines (AAL), Micron (MU), JC Penney (JCP), Pfizer (PFE) (more...) - 13F
-
Bristol-Myers Squibb to Take Part at the Citi 2016 Global Healthcare Conference
-
Complete Donald Trump Stock Impact Guide
-
Notable Mergers and Acquisitions 3/23: (MDRX) (BMY) (SUI) (TFSC)
-
Notable Analyst Rating Changes 12/2: (OZM) (BMY) (FIS) Upgraded; (MT) (ARMH) (GLBL) Downgraded
-
Market Wrap: Expected Fed Rate Hike Delay Boosts Markets; Citi, Goldman Mixed in Q3; Seagate Cuts Outlook
-
Pre-Open Stock Movers 10/15: (FPRX) (BOFI) (DXCM) Higher; (IMPR) (MTW) (VRX) (STX) (GRMN) (HCA) (NFLX) Lower (more...)
-
Ovid Therapeutics Announces Appointment of Dr. Anna Kazanchyan to Senior Vice President, Business Development
-
Bristol-Myers Squibb (BMY) to Acquire Flexus Biosciences in $1.25B Deal
-
Market Wrap: Adv. Q3 GDP Outpaces; Citi Lowers Q3 Results; Starbucks Percolates in Q3
-
Notable Mergers and Acquisitions of the Day 04/29: (BMY) (ATK) (CRUS) (ENDP)
-
Notable Analyst Rating Changes 10/28: (BMY) (FTI) (PTEN) Upgraded; (LYG) (PEG) (BIDU) Downgraded
-
Notable Analyst Rating Changes 09/16: (HUN) (BMY) (BX) Upgraded; (NVS) (PXD) (DSX) Downgraded
-
Notable 52-Week Highs and Lows of the Day 05/22: (MNKD) (CLNT) (BMY) High; (RAX) (RIGL) (CYCC) Low
-
Notable Analyst Rating Changes 05/22: (BMY) (CREE) (TEX) Upgraded; (IGTE) (CCL) (NCT) Downgraded
-
StreetInsider.com Pre-Open Movers 5/22: (ZLC) (SKS) (TOL) Higher; (UAN) (TGT) (SODA) Lower (more...)
-
Citi Upgrades Bristol-Myers Squibb Co. (BMY) to Buy
-
Notable Analyst Rating Changes 12/31: (FB) (PMFG) (BMY) Upgraded; (FOE) Downgraded
-
Citi Starts Bristol-Myers Squibb Co. (BMY) at Neutral
-
Notable Analyst Rating Changes 09/11: (BMY) (SYNC) (JAZZ) Upgraded; (SIRI) (TIBX) (GNOM) Downgraded
-
S&P 500 (SPY) is Going Higher Because Analyst Carter Worth Says So
-
Notable 52-Week Highs and Lows of the Day 06/29: (STZ) (DHI) (BMY) High; (RIMM) (NOK) (ANTH) Low
-
Citi Says Buy the Dip in Bristol-Myers (BMY) Shares
-
Amylin (AMLN) volatility flat on wide share price movement
-
Unusual 11 Mid-Day Movers 03/28: (OPHC) (AMLN) (PNR) Higher; (FSM) (USHS) (AONE) Lower
-
Morning Movers 03/28: (AMLN) (PNR) (YELP) (TNK) Higher; (FSM) (ALIM) (SNX) (CBK) Lower
-
Top 10 News Items 1/9-1/13: S&P Downgrades Slew of Euro Nations; JPMorgan Q4 Sales Disappoint; Bristol-Myer's Bid for Inhibitex Heats Up Drug Sector
-
Barclays 2012 Top Picks: Becoming Somewhat More Optimistic - Signs of Progress, Growth and Soft Landings
-
Notable 52-Week Highs and Lows of the Day 09/30: (VRUS) (BMY) High; (EK) (MU) (IR) Low
-
Pre-Open Movers 8/29: (NBG) (VQ) (PFE) Higher; (DNKN) (LDK) (RHI) Lower (more...)
-
Berkowitz's Fairholme Shows New Stake in Jefferies (JEF), Ups Stake In AIG (AIG), BofA (BAC), Citi (C); Liquidates Cisco (CSCO)
-
Notable Analyst Rating Changes 06/03: (DRYS) (FRX) (UA) Upgraded; (ALL) (FRO) (FDO) Downgraded
-
Berkowitz's Fairholme Picks Up Pharma Stakes, and Cisco (CSCO); Swaps General Growth (GGP) for Brookfield (BAM)
-
George Soros' Hedge Fund Slashes Stake In Gold ETF (GLD), Raises Stake in Citi (C) and AT&T (T)
-
Notable Analyst Rating Changes 03/31: (TSLA) (ARMH) (EMR) Upgraded; (OPEN) (CBE) (BMY) Downgraded
-
Notable 52-Week Highs and Lows of the Day 03/25: (ORCL) (BMY) (ACN) High; (BBY) (MNOV) Low
-
Daily State of the Markets 02/07: Irrelevant?
-
Paulson's Paulson & Co. Keeps Gold Rush Alive, Moves Out of Goldman and Increases Citi Stake (C, GS, ABX, APC, XOM, More...)
-
Citi on U.S. Major Pharmaceuticals: 2Q10 Outperformance Expected
-
Citi Maintains Estimates and 'Buy' Ratings on Merck (MRK) and Bristol-Myers (BMY); ADA Data Supports Our Januvia/Onglyza Long-Term Outlook
-
Notable Analyst Rating Changes 06/11: SQNM, SVVS, BMY, X Upgraded; LGF, AGU, WAG, THO Downgraded
-
Citi Upgrades Bristol-Myers Squibb (BMY) to Buy; Solid Pipeline Progress
-
Citi & Leerink Swann Upgrade Bristol-Myers (BMY) to Buy/Outperform
-
Notable Analyst Rating Changes 06/07: BMY, EGLE, CELG, NILE Upgraded; BP, TEL, SPWRA, ABT Downgraded
-
Citi 2010 Healthcare Conference Key Takeaways - MRK, PFE, BMY, ISIS, NPSP, & MYGN
-
Citi Comments on Disease-Modifying Antirheumatic Drug Market - 'Not Immune to a Tough Economy'
-
Active equity option families in first 30-minutes of trading according to Track Data are: C AAPL BAC BMY
-
Citi Issues Q1 Preview on U.S. Major Pharmaceuticals; Merck (MRK) Remains 'Top Pick'
-
Notable Analyst Rating Changes: MS, BA, UNH, INTC, UPL, FTO, More Upgraded; BMY, CHK, BSX, MELI, More Downgraded

